ABSTRACT
A 47-year-old woman with body temperature 35.6 ℃ took the 3rd COVID-19 vaccine shot at our clinic on Day 1. Since she felt chills and suffered from genital bleeding on Day 3, she visited our clinic to take a gynecological examination. Her temperature was 37.1 ℃ at that time. On Day 15, she suffered sustained symptoms of chills and general fatigue, and she went to another internal medicine clinic to take a medical care. However, her condition was unexplained and she was referred to a general hospital. On Day 16, she came to our clinic to confirm results of the gynecological examination. Her symptoms persisted even though the data showed no problems, so we prescribed her saikokeishikankyoto (SAKK) for only 3 days. On Day 19, SAKK dramatically improved her symptoms. On Day 37, her temperature was 36.2 ℃ without any symptoms.
ABSTRACT
In Kampo medicine, general fatigue is categorized as a symptom caused by qi deficiency according to the qi-blood-water criteria. However, in some patients with general fatigue, formulae for qi deficiency are not effective, and this might be because their chronic symptoms are associated with blood stagnation. Recently, we encountered ten patients (M/F 1/9, mean age 46 years, range 23-55 years) with general fatigue that was improved by agents for treating blood stagnation, such as keishibukuryogan and/or tokakujokito. These patients, who were mostly of medium build, complained of neck or shoulder stiffness (9/10), constipation (5/10), and blushing or hot flushes (5/10). They had no problem with appetite, except that 5 patients tended to overeat. Remarkable sublingual collateral vessels (8/10), paraumbilical tenderness (9/10) and periorbital dark circles (5/10) were observed on physical examination. The tongue and abdominal signs improved or had disappeared after treatment for 3 to 8 months. Our results suggest that patients with general fatigue, but who present with symptoms associated with blood stagnation, could be treated with drugs for blood stagnation such as keishibukuryogan and/or tokakujokito.
ABSTRACT
Hochu-ekki-to is one type of medicine that improves a Ki-deficiency. We therefore investigated the effects of Hochu-ekki-to on symptoms indicating a state of Ki-deficiency. In addition, we studied the effects of Hochu-ekki-to on blood pressure or body temperature. We studied 14 adult male patients with symptoms of general fatigue, lack of will power and appetite loss. We orally administered 7.5g of Hochu-ekki-to extract fine granules (EK-41) (Kanebo Pharm. Co, Tokyo, Japan) per day for four weeks. Before the oral administration of EK-41, and again four weeks later, we investigated any improvement of symptoms, and changes in the blood pressure or body temperature. After the oral administration of EK-41 for four weeks the general fatigue or lack of will power improved significantly (p<0.05), and we observed a significant increase in body temperature (p<0.05). The over all rate of “improvement” was 57.1%, and the rate for “slight improvement or more” was 71.4%. The oral administration of Hochu-ekki-to not only improved the symptoms of general fatigue and lack of will power but also raised the body temperature. This leads us to suspect that Hochu-ekki-to increased the metabolic function. We therefore consider the oral administration of Hochu-ekkito to be useful for the treatment of Ki-deficiency state patients with the symptoms of general fatigue and lack of will power.